Published date: 19 May 2020

Awarded contract - This means that the contract has been awarded to a supplier.


Closing: 14 April 2020

Contract summary

Industry

  • Business and management consultancy and related services - 79400000

Location of contract

England

Value of contract

£30,000

Procurement reference

NCL001-DN473477-33950644

Published date

19 May 2020

Closing date

14 April 2020

Contract start date

1 May 2020

Contract end date

31 December 2020

Contract type

Service contract

Procedure type

Other

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

Amyotrophic lateral sclerosis (ALS) - as with most other neurodegenerative diseases, including Alzheimer's and Parkinson's - is a major medical challenge and is having an ever-increasing impact upon the lives of patients, carers and indeed of society as a whole. Scientists at Durham (Chemistry Department) and Aberdeen Universities have recently designed, synthesised and identified a lead drug candidate with the potential for establishing a new treatment approach for ALS and with a longer-term potential of being effective for other neurodegenerative diseases.

The technology is now being patented and we are ready to develop a commercial vehicle to drive the drug development programme forwards and raise the necessary investment required for the next stages. The need for an experienced Business Executive/CEO, who has already delivered drugs to the market in the neurodegenerative area, is essential to support the Commercial Team and especially the CEO directly. Although two of the Team have commercial (spinout) experience (e.g. as CTO of LightOx who are successfully raising second phase major investment currently for LightOx), the successful launch of market leading drugs and the raising of the finance to make that happen is needed to successfully take the company forward.

In the longer term (such as Phase III raise of ca. £100+ million), such an executive might well be appointed as CEO, but in these early development stages, advise and business support is required

Award information

Awarded date

22 April 2020

Contract start date

1 May 2020

Contract end date

31 December 2020

Total value of contract

£30,000

This contract was awarded to 1 supplier.

DyoDelta Biosciences Ltd

Address

22a St. James's Square
London
Greater London
SW1Y 4JH

Reference

None

Supplier is SME?

Yes

Supplier is VCSE?

No

About the buyer

Contact name

Natalie Morton

Address

Newcastle University
Procurement Services, Kingsgate
Newcastle
NE1 7RU
England

Telephone

+44 1912086396

Email

natalie.morton@ncl.ac.uk